Gene deletion as opposed to insertion offers livestock producers practical advantages in terms of disease resistance, as in the case of pork, in addition to polled dairy and beef animals.

Currently, any form of genetic modification of livestock falls under the jurisdiction of the Food and Drug Administration.  This Agency requires extensive documentation relating to safety and efficacy. Personnel involved in review and authorization are unfamiliar with the science or practical application. Institutional reluctance to make decisions delayed the commercialization of AquaBounty® salmon for decades. Delays in adoption of gene deletion as currently applied in the E.U. and presumably China, places the U.S. at a competitive disadvantage. 

It is considered inappropriate for genetic modification of livestock destined for human consumption to fall under the Federal Food, Drug and Cosmetic Act administered by the FDA. In contrast it would be appropriate for the Agency to continue oversight of genetic modification of animals producing bio-pharmaceuticals and as organ downers

Although poultry breeders have committed to apply genetic technology to identify traits and for diagnostic procedures, it is inevitable that gene deletion will be accepted by consumers based on the potential advantages in terms of quality and cost.  At this time, technology developed in Israel involving gene insertion at the Grandparent level could resolve the problem of gender differentiation with advantages extending far beyond welfare considerations.

Gene deletion is evidently more acceptable than gene insertion although it will require considerable promotional effort and time to achieve commercialization.